OncoSec Medical To Present at 2014 DNA Vaccine Conference
July 17 2014 - 6:02AM
Business Wire
Leading the Discussion in Tumor Targeted
Immunotherapy
OncoSec Medical Inc. (OTCQB: ONCS), a company developing its
ImmunoPulse DNA-based intratumoral cancer immunotherapy, announces
that several company representatives will present at the
International Society of DNA Vaccines (ISDV) 2014 DNA Vaccine
Conference, being held July 21-23, 2014 at the Westin San Diego
Gaslamp Quarter Hotel in San Diego, CA.
As a Chairman’s Cup Sponsor for the event, OncoSec will be
prominently featured during the conference. Speakers will include
Robert Pierce, M.D., Chief Medical Officer, Soldano Ferrone, M.D.,
Ph.D., Scientific Advisory Board member, Richard Heller, Ph.D.,
Scientific Advisory Board member, and Holbrook Kohrt, M.D., Ph.D.,
clinical investigator.
Many of the leading investigators in cancer immunotherapy will
be attending to discuss the latest research in immune-modulating
antibodies, engineered T cells, gene delivery methods and
combination approaches in immunotherapy. This year, several
presentations will touch upon electroporation and its significance
as a safe and efficient means of non-viral gene delivery, and
discuss its clinical potential as an immuno-oncology platform.
There will also be a spotlight on the emerging field of
intratumoral immunotherapy. Dr. Pierce will lead this session of
the conference with his presentation “Intralesional DNA
Immunotherapy: Converting Anti-PD-1 Non-Responders to Responders”,
as part of the “Tumor Targeting” track.
“We are excited to have Dr. Holbrook Kohrt presenting his work
in a talk entitled Anti-CTLA-4 and CPG: Experience with Direct
Lesion Therapy," reports Dr. Pierce. “He and his colleagues at
Stanford have been on the forefront of intratumoral therapy and
thanks in part to these efforts, investigators are beginning to
realize the potential of intratumoral therapies to directly combat
the immunosuppressive mechanisms deployed by tumors. We are
witnessing the emergence of a new vision—one in which the optimal
future immunotherapy will combine intratumoral and systemic
approaches.”
Punit Dhillon, President and CEO, announced, “We are proud to be
a Chairman’s Cup Sponsor for this event. Each year, ISDV’s annual
DNA Vaccines conference has become larger and better attended by
key thought leaders in the space, and this year is no different.
Including OncoSec, several of the leading companies in developing
electroporation technology for DNA vaccines and immunotherapy will
be presenting and sharing data, and this year, OncoSec will lead
the discussion in the importance of developing intratumoral
immunotherapies using electroporation.”
About the International Society of DNA Vaccines
The International Society of DNA Vaccines is an organization
created to facilitate the advancement of therapeutic and preventive
DNA vaccines. The society is comprised of international scientists
and researchers who have dedicated their careers to improving world
health and the advancement of DNA vaccines and therapies.
About the 2014 DNA Vaccine Conference
DNA Vaccines 2014 is a scientific conference that offers major
opportunities for leading researchers worldwide to gather together
and report on the cutting-edge advances in research in the field of
DNA vaccines, debate accomplishments, and reveal new directions for
translational exploitation. Highlights include scientific plenary
sessions, scientific poster presentations and the attendance and
participation of internationally renowned scientists and
researchers.
About OncoSec Medical Inc.
OncoSec Medical Inc. is a biopharmaceutical company developing
its ImmunoPulse immunotherapy to treat solid tumors. OncoSec
Medical's core technology leverages a proprietary electroporation
platform to enhance the local delivery and uptake of DNA
IL-12 and other DNA-based immune-modulating agents. Clinical
studies of ImmunoPulse have demonstrated an acceptable safety
profile and preliminary evidence of anti-tumor activity in the
treatment of various skin cancers, as well as the potential to
initiate a systemic immune response without the systemic toxicities
associated with other treatments. OncoSec's clinical programs
currently include three Phase 2 trials targeting metastatic
melanoma, Merkel cell carcinoma and cutaneous T-cell lymphoma,
conducted in collaboration with several prominent academic medical
centers. As the company continues to evaluate ImmunoPulse in these
indications, it is also investigating additional indications and
combination therapeutic approaches. For more information, please
visit www.oncosec.com.
This press release contains forward-looking statements within
the meaning of the U.S. Private Securities Litigation Reform Act of
1995. Any statements in this release that are not historical facts
may be considered such “forward-looking statements.”
Forward-looking statements are based on management’s current
preliminary expectations and are subject to risks and
uncertainties, which may cause our results to differ materially and
adversely from the statements contained herein. Some of the
potential risks and uncertainties that could cause actual results
to differ from those predicted include our ability to raise
additional funding, our ability to acquire, develop or
commercialize new products, uncertainties inherent in pre-clinical
studies and clinical trials, unexpected new data, safety and
technical issues, competition, and market conditions. These and
additional risks and uncertainties are more fully described in
OncoSec Medical’s filings with the Securities and Exchange
Commission. Undue reliance should not be placed on forward-looking
statements, which speak only as of the date they are made. OncoSec
Medical disclaims any obligation to update any forward-looking
statements to reflect new information, events or circumstances
after the date they are made, or to reflect the occurrence of
unanticipated events.
OncoSec Medical Inc.Investor Relations:Veronica Vallejo,
CFO855-662-6732investors@oncosec.com
OncoSec Medical (NASDAQ:ONCS)
Historical Stock Chart
From Apr 2024 to May 2024
OncoSec Medical (NASDAQ:ONCS)
Historical Stock Chart
From May 2023 to May 2024